Torsemide (Torem, Demadex)

Torsemide (also spelled torasemide, brand names Torem, Unat and Demadex) is a loop diuretic. That puts it in the substance class that intervenes most strongly in the kidney's water and salt balance. Within the class torsemide is the more modern member: same target as furosemide, but clearly more predictable absorption and a longer duration of action.

The active ingredient has been approved and widely prescribed for decades. The evidence base is correspondingly solid, the side effect profile is known and the limits are cleanly described - which sets torsemide apart from many experimental compounds.

This information is for research and educational purposes only. No medical advice.

The target sits in the thick ascending limb of the loop of Henle. There the kidney normally recovers a large share of sodium from the primary urine via the Na-K-2Cl cotransporter (NKCC2). Torsemide blocks that transporter. Sodium, potassium and chloride stay in the urine, water follows the salt osmotically, urine volume rises.

Because this kidney segment handles such a large share of sodium recovery, the effect is powerful. And that is exactly where the risk comes from: what leaves the body is never just water, it is always electrolyte too. Studies also point to an anti-aldosterone component that separates torsemide from a pure NKCC2 blocker.

Both inhibit the same transporter. The difference is kinetic and matters in practice:

• Bioavailability: torsemide sits at around 80 to 90 percent and barely varies. Furosemide scatters widely between people and even between single doses. Vargo et al. showed this in a 1995 crossover design.
• Duration: torsemide acts for about 6 to 8 hours, furosemide clearly shorter. That gives a flatter curve instead of a short and violent peak.
• Elimination: torsemide is cleared mainly hepatically via CYP2C9, only a smaller share renally. Furosemide depends more on kidney function.
• Hard endpoints: despite the better kinetics, TRANSFORM-HF found no mortality difference in 2023. Easier to control does not automatically mean better outcomes.

The TORIC observational study (Cosín and Díez, 2002) followed around 1400 people with chronic heart failure over twelve months and reported lower mortality plus more frequent functional improvement under torsemide than under furosemide and other diuretics. Murray et al. described fewer readmissions and less fatigue in a 2001 open randomized one-year trial.

The methodologically strongest work is TRANSFORM-HF (Mentz et al., JAMA 2023): over 2800 participants, randomized and with no difference in all-cause mortality between torsemide and furosemide. The honest summary: pharmacokinetically superior, equivalent on the hard clinical endpoint.

The key point with this substance class is not potency, it is what gets flushed out alongside the water. Torsemide takes potassium, sodium, magnesium and chloride with it.

• Potassium: the loss is the best documented effect of the class. Low potassium is linked in the literature to muscle weakness, cramps and cardiac arrhythmia.
• Volume: fluid loss that happens too fast leads per the literature to blood pressure drops, orthostatic dizziness and a rise in urea and creatinine.
• Combinations: NSAIDs, ACE inhibitors, sartans, further diuretics and digitalis preparations add to the risk instead of cushioning it.
• Reality check: rapid weight loss over a few days is water. That is not progress, it is a warning sign.

• Hypokalemia, hyponatremia, hypomagnesemia, hypochloremic alkalosis.
• Dehydration, blood pressure drops, dizziness, tachycardia, prerenal azotemia.
• Hyperuricemia with possible gout flares.
• Mild, dose-dependent increases in blood glucose and blood lipids.
• Ototoxicity as a class effect, above all at very high or rapidly infused intravenous doses.
• Interactions via CYP2C9 as well as with lithium and aminoglycoside antibiotics.

Store dry, at room temperature and protected from light. Keep in the closed bottle, out of reach of children.